Literature DB >> 8892767

Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine.

M Ishihara1, H Sato, H Tateishi, T Kawagoe, Y Shimatani, S Kurisu, K Sakai.   

Abstract

The no-reflow phenomenon is observed as reduction of coronary blood flow on the angiograms (angiographic no-reflow) after immediate percutaneous transluminal coronary angioplasty (PTCA) in patients with acute myocardial infarction (AMI). To assess whether a potent coronary microvascular dilator--papaverine--could attenuate the no-reflow phenomenon, nine patients with AMI who were found to have angiographic no-reflow after PTCA were studied. Angiographic no-reflow was defined as the Thrombolysis in Myocardial Infarction flow grade 1 or 2 without any mechanical obstructions in the epicardial artery. A bolus dose of 10 mg of intracoronary papaverine was administered, and the flow grade was again evaluated. Intracoronary papaverine caused a significant improvement of the flow grade (p= 0.0152). The number of cineframes that were required for the contrast medium to pass two selected landmarks on the angiograms also significantly decreased (41 +/- 17 frames to 18 +/- 8 frames, p= 0.0039). Thus intracoronary papaverine attenuated angiographic no-reflow that occurred after PTCA for AMI.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892767     DOI: 10.1016/s0002-8703(96)90005-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Coronary No-reflow Phenomenon.

Authors:  Shereif H Rezkalla; Robert A Kloner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-05

Review 2.  Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.

Authors:  Vijayalakshmi Kunadian; Cafer Zorkun; Scott P Williams; Leah H Biller; Alexandra M Palmer; Katherine J Ogando; Michelle E Lew; Navin Nethala; William J Gibson; Susan J Marble; Jacqueline L Buros; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2008-09-26       Impact factor: 2.300

3.  Complications of coronary intervention: device embolisation, no-reflow, air embolism.

Authors:  Debabrata Dash
Journal:  Heart Asia       Date:  2013-04-30

Review 4.  Reperfusion revisited: beyond TIMI 3 flow.

Authors:  J P Gassler; E J Topol
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

5.  Multivessel coronary thrombosis, acute myocardial infarction, and no reflow in a patient with essential thrombocythaemia.

Authors:  H Terada; H Satoh; A Uehara
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

6.  The relationship of intracoronary stent placement following thrombolytic therapy to tissue level perfusion.

Authors:  C Michael Gibson; Daniel Frisch; Sabina A Murphy; Steven G Gourlay; Raymond Gibbons; Kenneth W Baran; Michel Nguyen; Sebastian Palmeri; Hal V Barron
Journal:  J Thromb Thrombolysis       Date:  2002-04       Impact factor: 2.300

7.  Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.

Authors:  G Montalescot; H R Andersen; D Antoniucci; A Betriu; M J de Boer; L Grip; F J Neumann; M T Rothman
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

8.  Microvascular obstruction after successful fibrinolytic therapy in acute myocardial infarction. Comparison of reteplase vs reteplase+abciximab: A cardiovascular magnetic resonance study.

Authors:  Antonello Zoni; Peter Knoll; Tiziano Gherli
Journal:  Heart Int       Date:  2006-05-28

9.  The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

Authors:  Sheraz A Nazir; Jamal N Khan; Islam Z Mahmoud; John P Greenwood; Daniel J Blackman; Vijay Kunadian; Martin Been; Keith R Abrams; Robert Wilcox; A A Jennifer Adgey; Gerry P McCann; Anthony H Gershlick
Journal:  Trials       Date:  2014-09-25       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.